Studies of catecholamine metabolism in schizophrenia/psychosis-I
Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHP...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 1993-02, Vol.8 (2), p.97-109 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109 |
|---|---|
| container_issue | 2 |
| container_start_page | 97 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 8 |
| creator | MAAS, J. W CONTRERAS, S. A MILLER, A. L BERMAN, N BOWDEN, C. L JAVORS, M. A SELESHI, E WEINTRAUB, S |
| description | Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid (CSF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HVA levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HVA correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well. |
| doi_str_mv | 10.1038/npp.1993.11 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75671513</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75671513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2651-f3569c7c7b2325768eb0d9be082000a96cc11b1f1de30188f9016060d426cc433</originalsourceid><addsrcrecordid>eNo9kM1Lw0AQRxdRaq2ePAs5iBdJO5NNstmbUvwoFDyo0Nuy2WzoSr7MJIf615vQ0NMc3uPH8Bi7RVgi8GRVNc0SpeRLxDM2RxGCH_Nwd87mkEjuI-e7S3ZF9AOAkYiTGZsloUDkwZw9fXZ95ix5de4Z3Vmzrwtdusp6pe10WheOSs9VHpm9-6ubfWsrp1cNHQaRHPmba3aR64LszXQX7Pv15Wv97m8_3jbr561vgjhCP-dRLI0wIg14MD5hU8hkaiEJAEDL2BjEFHPMLAdMklwCxhBDFgYDCjlfsIfjbtPWv72lTpWOjC0KXdm6JyWiWGCEo_h4FE1bE7U2V03rSt0eFIIae6mhlxp7qSHBgt1Ns31a2uzkToEGfj9xTUYXeasr4-ikhZGQMpL8Hy0sciE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75671513</pqid></control><display><type>article</type><title>Studies of catecholamine metabolism in schizophrenia/psychosis-I</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>MAAS, J. W ; CONTRERAS, S. A ; MILLER, A. L ; BERMAN, N ; BOWDEN, C. L ; JAVORS, M. A ; SELESHI, E ; WEINTRAUB, S</creator><creatorcontrib>MAAS, J. W ; CONTRERAS, S. A ; MILLER, A. L ; BERMAN, N ; BOWDEN, C. L ; JAVORS, M. A ; SELESHI, E ; WEINTRAUB, S</creatorcontrib><description>Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid (CSF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HVA levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HVA correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/npp.1993.11</identifier><identifier>PMID: 8471132</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Adult ; Adult and adolescent clinical studies ; Aged ; Analysis of Variance ; Biological and medical sciences ; Blood Platelets - enzymology ; Catecholamines - metabolism ; Debrisoquin ; Double-Blind Method ; Homovanillic Acid - metabolism ; Humans ; In Vitro Techniques ; Male ; Medical sciences ; Methoxyhydroxyphenylglycol - metabolism ; Middle Aged ; Monoamine Oxidase - blood ; Psychology. Psychoanalysis. Psychiatry ; Psychometrics ; Psychopathology. Psychiatry ; Psychoses ; Schizophrenia - enzymology ; Schizophrenia - metabolism ; Schizophrenic Psychology</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 1993-02, Vol.8 (2), p.97-109</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2651-f3569c7c7b2325768eb0d9be082000a96cc11b1f1de30188f9016060d426cc433</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4579959$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8471132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAAS, J. W</creatorcontrib><creatorcontrib>CONTRERAS, S. A</creatorcontrib><creatorcontrib>MILLER, A. L</creatorcontrib><creatorcontrib>BERMAN, N</creatorcontrib><creatorcontrib>BOWDEN, C. L</creatorcontrib><creatorcontrib>JAVORS, M. A</creatorcontrib><creatorcontrib>SELESHI, E</creatorcontrib><creatorcontrib>WEINTRAUB, S</creatorcontrib><title>Studies of catecholamine metabolism in schizophrenia/psychosis-I</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid (CSF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HVA levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HVA correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - enzymology</subject><subject>Catecholamines - metabolism</subject><subject>Debrisoquin</subject><subject>Double-Blind Method</subject><subject>Homovanillic Acid - metabolism</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methoxyhydroxyphenylglycol - metabolism</subject><subject>Middle Aged</subject><subject>Monoamine Oxidase - blood</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychometrics</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Schizophrenia - enzymology</subject><subject>Schizophrenia - metabolism</subject><subject>Schizophrenic Psychology</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1Lw0AQRxdRaq2ePAs5iBdJO5NNstmbUvwoFDyo0Nuy2WzoSr7MJIf615vQ0NMc3uPH8Bi7RVgi8GRVNc0SpeRLxDM2RxGCH_Nwd87mkEjuI-e7S3ZF9AOAkYiTGZsloUDkwZw9fXZ95ix5de4Z3Vmzrwtdusp6pe10WheOSs9VHpm9-6ubfWsrp1cNHQaRHPmba3aR64LszXQX7Pv15Wv97m8_3jbr561vgjhCP-dRLI0wIg14MD5hU8hkaiEJAEDL2BjEFHPMLAdMklwCxhBDFgYDCjlfsIfjbtPWv72lTpWOjC0KXdm6JyWiWGCEo_h4FE1bE7U2V03rSt0eFIIae6mhlxp7qSHBgt1Ns31a2uzkToEGfj9xTUYXeasr4-ikhZGQMpL8Hy0sciE</recordid><startdate>199302</startdate><enddate>199302</enddate><creator>MAAS, J. W</creator><creator>CONTRERAS, S. A</creator><creator>MILLER, A. L</creator><creator>BERMAN, N</creator><creator>BOWDEN, C. L</creator><creator>JAVORS, M. A</creator><creator>SELESHI, E</creator><creator>WEINTRAUB, S</creator><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199302</creationdate><title>Studies of catecholamine metabolism in schizophrenia/psychosis-I</title><author>MAAS, J. W ; CONTRERAS, S. A ; MILLER, A. L ; BERMAN, N ; BOWDEN, C. L ; JAVORS, M. A ; SELESHI, E ; WEINTRAUB, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2651-f3569c7c7b2325768eb0d9be082000a96cc11b1f1de30188f9016060d426cc433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - enzymology</topic><topic>Catecholamines - metabolism</topic><topic>Debrisoquin</topic><topic>Double-Blind Method</topic><topic>Homovanillic Acid - metabolism</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methoxyhydroxyphenylglycol - metabolism</topic><topic>Middle Aged</topic><topic>Monoamine Oxidase - blood</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychometrics</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Schizophrenia - enzymology</topic><topic>Schizophrenia - metabolism</topic><topic>Schizophrenic Psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAAS, J. W</creatorcontrib><creatorcontrib>CONTRERAS, S. A</creatorcontrib><creatorcontrib>MILLER, A. L</creatorcontrib><creatorcontrib>BERMAN, N</creatorcontrib><creatorcontrib>BOWDEN, C. L</creatorcontrib><creatorcontrib>JAVORS, M. A</creatorcontrib><creatorcontrib>SELESHI, E</creatorcontrib><creatorcontrib>WEINTRAUB, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAAS, J. W</au><au>CONTRERAS, S. A</au><au>MILLER, A. L</au><au>BERMAN, N</au><au>BOWDEN, C. L</au><au>JAVORS, M. A</au><au>SELESHI, E</au><au>WEINTRAUB, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Studies of catecholamine metabolism in schizophrenia/psychosis-I</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>1993-02</date><risdate>1993</risdate><volume>8</volume><issue>2</issue><spage>97</spage><epage>109</epage><pages>97-109</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid (CSF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HVA levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HVA correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well.</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>8471132</pmid><doi>10.1038/npp.1993.11</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 1993-02, Vol.8 (2), p.97-109 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75671513 |
| source | MEDLINE; SpringerNature Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Adult and adolescent clinical studies Aged Analysis of Variance Biological and medical sciences Blood Platelets - enzymology Catecholamines - metabolism Debrisoquin Double-Blind Method Homovanillic Acid - metabolism Humans In Vitro Techniques Male Medical sciences Methoxyhydroxyphenylglycol - metabolism Middle Aged Monoamine Oxidase - blood Psychology. Psychoanalysis. Psychiatry Psychometrics Psychopathology. Psychiatry Psychoses Schizophrenia - enzymology Schizophrenia - metabolism Schizophrenic Psychology |
| title | Studies of catecholamine metabolism in schizophrenia/psychosis-I |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A59%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Studies%20of%20catecholamine%20metabolism%20in%20schizophrenia/psychosis-I&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=MAAS,%20J.%20W&rft.date=1993-02&rft.volume=8&rft.issue=2&rft.spage=97&rft.epage=109&rft.pages=97-109&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/npp.1993.11&rft_dat=%3Cproquest_cross%3E75671513%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75671513&rft_id=info:pmid/8471132&rfr_iscdi=true |